These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
336 related articles for article (PubMed ID: 31165933)
1. Efficacy and safety of anthralin in combination with diphenylcyclopropenone in the treatment of alopecia areata: a retrospective case series. Nasimi M; Ghandi N; Abedini R; Mirshamsi A; Shakoei S; Seirafi H Arch Dermatol Res; 2019 Oct; 311(8):607-613. PubMed ID: 31165933 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of diphenylcyclopropenone alone or in combination with anthralin in the treatment of chronic extensive alopecia areata: a retrospective case series. Durdu M; Özcan D; Baba M; Seçkin D J Am Acad Dermatol; 2015 Apr; 72(4):640-50. PubMed ID: 25653027 [TBL] [Abstract][Full Text] [Related]
3. Treatment of chronic extensive alopecia areata by diphenylcyclopropenone alone versus in combination with anthralin. Ibrahim SA; Esawy AM; Abdelshafy AS Dermatol Ther; 2019 Sep; 32(5):e13010. PubMed ID: 31237076 [TBL] [Abstract][Full Text] [Related]
4. A randomized trial of diphenylcyclopropenone (DPCP) combined with anthralin versus DPCP alone for treating moderate to severe alopecia areata. Ghandi N; Daneshmand R; Hatami P; Abedini R; Nasimi M; Aryanian Z; Vance TM Int Immunopharmacol; 2021 Oct; 99():107971. PubMed ID: 34298402 [TBL] [Abstract][Full Text] [Related]
5. Clinical Efficacy of Diphenylcyclopropenone in Alopecia Areata: Retrospective Data Analysis of 50 Patients. Chiang KS; Mesinkovska NA; Piliang MP; Bergfeld WF J Investig Dermatol Symp Proc; 2015 Nov; 17(2):50-5. PubMed ID: 26551948 [TBL] [Abstract][Full Text] [Related]
6. Topical immunomodulation with diphenylcyclopropenone for alopecia areata: the Lebanese experience. El Khoury J; Abd-el-Baki J; Succariah F; Abbas O; Kibbi AG; Kurban M Int J Dermatol; 2013 Dec; 52(12):1551-6. PubMed ID: 24134785 [TBL] [Abstract][Full Text] [Related]
7. Subclinical sensitization with diphenylcyclopropenone is sufficient for the treatment of alopecia areata: Retrospective analysis of 159 cases. Choe SJ; Lee S; Pi LQ; Keum DI; Lee CH; Kim BJ; Lee WS J Am Acad Dermatol; 2018 Mar; 78(3):515-521.e4. PubMed ID: 29108907 [TBL] [Abstract][Full Text] [Related]
8. Topical immunotherapy of severe alopecia areata with diphenylcyclopropenone (DPCP): experience in an Iranian population. Aghaei S BMC Dermatol; 2005 May; 5():6. PubMed ID: 15918897 [TBL] [Abstract][Full Text] [Related]
9. Treatment of pediatric alopecia areata with anthralin: A retrospective study of 37 patients. Wu SZ; Wang S; Ratnaparkhi R; Bergfeld WF Pediatr Dermatol; 2018 Nov; 35(6):817-820. PubMed ID: 30338548 [TBL] [Abstract][Full Text] [Related]
10. A prospective comparative study of two regimens of diphenylcyclopropenone (DPCP) in the treatment of alopecia areata. Al Bazzal A; Hatami P; Abedini R; Etesami I; Ayanian Z; Ghandi N Int Immunopharmacol; 2021 Dec; 101(Pt B):108186. PubMed ID: 34710658 [TBL] [Abstract][Full Text] [Related]
11. Topical immunotherapy in combination with anthralin in the treatment of refractory alopecia areata. Kagami S; Kishi Y; Hino H J Cosmet Dermatol; 2020 Sep; 19(9):2411-2414. PubMed ID: 32621407 [TBL] [Abstract][Full Text] [Related]
12. The use of topical diphenylcyclopropenone for the treatment of extensive alopecia areata. Cotellessa C; Peris K; Caracciolo E; Mordenti C; Chimenti S J Am Acad Dermatol; 2001 Jan; 44(1):73-6. PubMed ID: 11148480 [TBL] [Abstract][Full Text] [Related]
13. Diphenylcyclopropenone (diphencyprone, DPCP) in the treatment of chronic severe alopecia areata (AA). Galadari I; Rubaie S; Alkaabi J; Galadari H Eur Ann Allergy Clin Immunol; 2003 Dec; 35(10):397-401. PubMed ID: 14768526 [TBL] [Abstract][Full Text] [Related]
14. Higher concentrations of dithranol appear to induce hair growth even in severe alopecia areata. Ngwanya MR; Gray NA; Gumedze F; Ndyenga A; Khumalo NP Dermatol Ther; 2017 Jul; 30(4):. PubMed ID: 28598005 [TBL] [Abstract][Full Text] [Related]
15. Is the severity of initial sensitization to diphenylcyclopropenone in alopecia areata patients predictive of the final clinical response? Ghandi N; Seifi G; Nasimi M; Abedini R; Mirabedian S; Etesami I; Ehsani A Dermatol Ther; 2021 Nov; 34(6):e15118. PubMed ID: 34464020 [TBL] [Abstract][Full Text] [Related]
16. Topical immunotherapy with diphenylcyclopropenone in the treatment of chronic extensive alopecia areata. Sotiriadis D; Patsatsi A; Lazaridou E; Kastanis A; Vakirlis E; Chrysomallis F Clin Exp Dermatol; 2007 Jan; 32(1):48-51. PubMed ID: 17004987 [TBL] [Abstract][Full Text] [Related]
17. Serum level of IL-4 predicts response to topical immunotherapy with diphenylcyclopropenone in alopecia areata. Gong Y; Zhao Y; Zhang X; Qi S; Li S; Ye Y; Yang J; Caulloo S; McElwee KJ; Zhang X Exp Dermatol; 2020 Mar; 29(3):231-238. PubMed ID: 30047620 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of diphenylcyclopropenone among Chinese patients with steroid resistant and extensive alopecia areata. Luk NM; Chiu LS; Lee KC; Chau CT; Lee VW; Chang M; Lam YK; Lee HC J Eur Acad Dermatol Venereol; 2013 Mar; 27(3):e400-5. PubMed ID: 23057682 [TBL] [Abstract][Full Text] [Related]
19. A systematic review on the treatment of pediatric severe alopecia areata by topical immunotherapy or Anthralin (contact sensitization) or low-level light/laser therapy (LLLT): focus on efficacy, safety, treatment duration, recurrence, and follow-up based on clinical studies. Behrangi E; Roohaninasab M; Sadeghzadeh-Bazargan A; Najar Nobari N; Ghassemi M; Seirafianpour F; Goodarzi A; Dodangeh M J Cosmet Dermatol; 2022 Jul; 21(7):2727-2741. PubMed ID: 34606676 [TBL] [Abstract][Full Text] [Related]